Ruzinurad

Ruzinurad
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 1-(6-Bromoquinolin-4-yl)sulfanylcyclobutane-1-carboxylic acid;
CAS Number	1638327-48-6;
PubChem CID	86294127;
ChemSpider	58872931;
UNII	UP8J9CA76I;
ChEMBL	ChEMBL3746329;
Chemical and physical data
Formula	C14H12BrNO2S
Molar mass	338.22 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC(C1)(C(=O)O)SC2=C3C=C(C=CC3=NC=C2)Br;
	InChI InChI=1S/C14H12BrNO2S/c15-9-2-3-11-10(8-9)12(4-7-16-11)19-14(13(17)18)5-1-6-14/h2-4,7-8H,1,5-6H2,(H,17,18); Key:QGBWIYLNOBYNDL-UHFFFAOYSA-N;

Ruzinurad (SHR4640) is a selective urate transporter 1 (URAT1) inhibitor in development for hyperuricaemia and gout. It is developed by Jiangsu Hengrui.^[1]^[2]^[3]^[4]^[5]^[6]

References

^ Lin, Yanwei; Chen, Xiaoxiang; Ding, Huihua; Ye, Ping; Gu, Jieruo; Wang, Xiaoxia; Jiang, Zhenyu; Li, Detian; Wang, Zhongming; Long, Wubin; Li, Zhijun; Jiang, Gengru; Li, Xiaomei; Bi, Liqi; Jiang, Lindi; Wu, Jian; Guo, Lian; Cai, Xiaoyan; Lu, Xin; Chen, Qinkai; Chen, Hong; Peng, Ai; Zuo, Xiaoxia; Ning, Rui; Zhang, Zhe; Tai, Yanfei; Zhang, Tao; Bao, Chunde (3 November 2021). "Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study". Rheumatology. 60 (11): 5089–5097. doi:10.1093/rheumatology/keab198. ISSN 1462-0332. PMID 33693494.
^ Wang, Chenjing; Yu, Qing; Jiang, Xin; Deng, Yujie; Sun, Feifei; Li, Xin; Tao, Ye; Lin, Pingping; Ma, Yaping; Zhu, Yuxian; Li, Chengqian; Cao, Yu (February 2023). "A Drug–Drug Interaction Study of a Novel Selective Urate Reabsorption Inhibitor, SHR4640, and Xanthine Oxidase Inhibitor, Febuxostat, in Patients With Primary Hyperuricemia". The Journal of Clinical Pharmacology. 63 (2): 239–249. doi:10.1002/jcph.2159. PMID 36131360. S2CID 252437511.
^ Lin, Yanwei; Chen, Xiaoxiang; Ding, Huihua; Ye, Ping; Gu, Jieruo; Wang, Xiaoxia; Jiang, Zhenyu; Li, Detian; Wang, Zhongming; Long, Wubin; Li, Zhijun; Jiang, Gengru; Li, Xiaomei; Bi, Liqi; Jiang, Lindi; Wu, Jian; Guo, Lian; Cai, Xiaoyan; Lu, Xin; Chen, Qinkai; Chen, Hong; Peng, Ai; Zuo, Xiaoxia; Ning, Rui; Zhang, Zhe; Tai, Yanfei; Zhang, Tao; Bao, Chunde (3 November 2021). "Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study". Rheumatology. 60 (11): 5089–5097. doi:10.1093/rheumatology/keab198. PMID 33693494.
^ Liang, Beibei; Wang, Jin; Bai, Nan; Zhuo, Jiaju; Wang, Rui; Lin, Hongda; Cai, Yun (April 2023). "Effect of Food on the Pharmacokinetics and Pharmacodynamics of a Single Oral Dose of SHR4640, a Selective Urate Transporter 1 Inhibitor, in Healthy Chinese Male Volunteers". Clinical Pharmacology in Drug Development. 12 (4): 392–396. doi:10.1002/cpdd.1191. ISSN 2160-7648. PMID 36317751. S2CID 253245027.
^ "A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout". www.clinicaltrials.gov. Retrieved 11 November 2023.
^ Tang, Honghu; Cui, Beibei; Chen, Yiyu; Chen, Lin; Wang, Zhihong; Zhang, Ning; Yang, Yanlan; Wang, Xiaodong; Xie, Xiangliang; Sun, Lingyun; Dang, Wantai; Wang, Xianyang; Li, Runzi; Zou, Jianjun; Zhao, Yi; Liu, Yi (January 2022). "Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study". Therapeutic Advances in Musculoskeletal Disease. 14: 1759720X2110673. doi:10.1177/1759720X211067304. ISSN 1759-720X. PMC 8808016. PMID 35126684.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] Lin, Yanwei; Chen, Xiaoxiang; Ding, Huihua; Ye, Ping; Gu, Jieruo; Wang, Xiaoxia; Jiang, Zhenyu; Li, Detian; Wang, Zhongming; Long, Wubin; Li, Zhijun; Jiang, Gengru; Li, Xiaomei; Bi, Liqi; Jiang, Lindi; Wu, Jian; Guo, Lian; Cai, Xiaoyan; Lu, Xin; Chen, Qinkai; Chen, Hong; Peng, Ai; Zuo, Xiaoxia; Ning, Rui; Zhang, Zhe; Tai, Yanfei; Zhang, Tao; Bao, Chunde (3 November 2021). "Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study". Rheumatology. 60 (11): 5089–5097. doi:10.1093/rheumatology/keab198. ISSN 1462-0332. PMID 33693494.

[2] Wang, Chenjing; Yu, Qing; Jiang, Xin; Deng, Yujie; Sun, Feifei; Li, Xin; Tao, Ye; Lin, Pingping; Ma, Yaping; Zhu, Yuxian; Li, Chengqian; Cao, Yu (February 2023). "A Drug–Drug Interaction Study of a Novel Selective Urate Reabsorption Inhibitor, SHR4640, and Xanthine Oxidase Inhibitor, Febuxostat, in Patients With Primary Hyperuricemia". The Journal of Clinical Pharmacology. 63 (2): 239–249. doi:10.1002/jcph.2159. PMID 36131360. S2CID 252437511.

[3] Lin, Yanwei; Chen, Xiaoxiang; Ding, Huihua; Ye, Ping; Gu, Jieruo; Wang, Xiaoxia; Jiang, Zhenyu; Li, Detian; Wang, Zhongming; Long, Wubin; Li, Zhijun; Jiang, Gengru; Li, Xiaomei; Bi, Liqi; Jiang, Lindi; Wu, Jian; Guo, Lian; Cai, Xiaoyan; Lu, Xin; Chen, Qinkai; Chen, Hong; Peng, Ai; Zuo, Xiaoxia; Ning, Rui; Zhang, Zhe; Tai, Yanfei; Zhang, Tao; Bao, Chunde (3 November 2021). "Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study". Rheumatology. 60 (11): 5089–5097. doi:10.1093/rheumatology/keab198. PMID 33693494.

[4] Liang, Beibei; Wang, Jin; Bai, Nan; Zhuo, Jiaju; Wang, Rui; Lin, Hongda; Cai, Yun (April 2023). "Effect of Food on the Pharmacokinetics and Pharmacodynamics of a Single Oral Dose of SHR4640, a Selective Urate Transporter 1 Inhibitor, in Healthy Chinese Male Volunteers". Clinical Pharmacology in Drug Development. 12 (4): 392–396. doi:10.1002/cpdd.1191. ISSN 2160-7648. PMID 36317751. S2CID 253245027.

[5] "A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout". www.clinicaltrials.gov. Retrieved 11 November 2023.

[6] Tang, Honghu; Cui, Beibei; Chen, Yiyu; Chen, Lin; Wang, Zhihong; Zhang, Ning; Yang, Yanlan; Wang, Xiaodong; Xie, Xiangliang; Sun, Lingyun; Dang, Wantai; Wang, Xianyang; Li, Runzi; Zou, Jianjun; Zhao, Yi; Liu, Yi (January 2022). "Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study". Therapeutic Advances in Musculoskeletal Disease. 14: 1759720X2110673. doi:10.1177/1759720X211067304. ISSN 1759-720X. PMC 8808016. PMID 35126684.

[1]

[2]

[3]

[4]

[5]

[6]